Darmiyan

Darmiyan has developed a novel AI-powered diagnostic platform, BrainSee, which received De Novo FDA approval for predicting the 5-year prognosis of patients with mild cognitive impairment (MCI). The technology analyzes routine MRI scans at a voxel level to create a 'virtual microscope' of the brain, aiming to detect neurodegenerative changes years before clinical symptoms manifest. Backed by validation studies showing ~90% accuracy and investment from pharmaceutical giant Eisai, Darmiyan is positioned to address a critical gap in early Alzheimer's disease detection and intervention monitoring. The company operates as a private, commercial-stage diagnostics firm with a clear focus on revolutionizing the brain health paradigm.

Patented medical AI and image processing software (DarmiScope) that acts as a 'Virtual Microscope,' analyzing standard brain MRI scans at the voxel level to quantify microscopic changes in brain tissue architecture between cells.

Darmiyan competes in the neurodiagnostic space against companies developing blood-based biomarkers (e.g., companies like C2N Diagnostics, Quest Diagnostics), advanced PET imaging ligands, and other AI-based MRI analysis tools. Its key differentiation is the FDA-approved prognostic claim for MCI using only standard MRI, offering a non-invasive, widely accessible alternative to PET or cerebrospinal fluid tests.